BiotechTube
Dignify Therapeutics

Dignify Therapeutics

Chapel Hill, United States· Est.
dignifytherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3M

Overview

Dignify Therapeutics, founded in 2017 and based in Chapel Hill, NC, is a private biotech targeting a significant unmet need in neuro-urology and neuro-gastroenterology. The company is developing novel, patient-administered therapies designed to trigger bladder and bowel emptying at will, aiming to restore dignity and independence. Backed by venture capital and non-dilutive NIH grants, Dignify is advancing its pipeline through a repositioning strategy led by an experienced team of serial entrepreneurs. The company is entering a pivotal growth phase, as evidenced by recent key executive hires.

UrologyGastroenterologyNeurology

Technology Platform

Drug repositioning strategy to develop 'on-demand' small molecule therapies that trigger controlled emptying of the bladder and bowel.

Funding History

1
Total raised:$3M
Seed$3M

Opportunities

The massive, underserved market of elderly and neurologically impaired patients with bowel/bladder dysfunction represents a multi-billion dollar opportunity.
A successful on-demand therapy could become a new standard of care, displacing invasive and inconvenient current methods.
The drug repositioning strategy offers a faster, de-risked development pathway with known compound safety.

Risk Factors

High clinical trial risk where candidates may fail on efficacy or safety in later-stage studies.
Dependence on future fundraising for costly Phase 3 trials and commercialization, leading to potential dilution.
Regulatory hurdles and potential challenges in achieving market access and reimbursement for a novel therapeutic paradigm.

Competitive Landscape

Competition includes standard-of-care interventions like catheters, suppositories, and manual evacuation, which are invasive but established. Limited pharmacological competitors exist, but none offer a true patient-controlled, on-demand triggering mechanism. Dignify's unique approach could carve out a distinct and defensible market niche if clinically validated.

More companies in Small Molecule Drugs →More companies in United States →